Leishmania PROTEASES: NEW TARGETS FOR RATIONAL DRUG DEVELOPMENT

被引：23
作者：
da Silva-Lopez, Raquel Elisa [1 ]
机构：
[1] Fundacao Oswaldo Cruz, Inst Tecnol Farmacos Farmanguinhos, BR-21045900 Rio De Janeiro, Brazil
来源：
QUIMICA NOVA | 2010年 / 33卷 / 07期
关键词：
proteases; Leishmania; chemotheraphy; MAJOR SURFACE GLYCOPROTEIN; SERINE-PROTEASE; AMAZONENSIS PROMASTIGOTES; SUBCELLULAR-LOCALIZATION; IMMUNE-RESPONSE; GP63; INHIBITORS; PEPTIDASES; THERAPY; METALLOPROTEASE;
D O I：
10.1590/S0100-40422010000700022
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Leishmania PROTEASES: NEW TARGETS FOR RATIONAL DRUG DEVELOPMENT. Leishmania causes tegumental and visceral diseases called leishmaniasis. Disease control is possible interrupting the transmission cycle, but HIV co-infection, chemotheraphy toxicity and lack of a vaccine are paramount difficulties. So, is necessary to study new Leishmania molecules and investigate the possibility to develop rational drugs using these molecules as targets. Leishmania express many peptidases during their life, and cysteine are the most abundant protease and many inhibitors were developed but failed to kill parasites. On the other hand, inhibitors of serine proteases killed promastigotes, indicating the possibility of these enzymes to be important targets in the development of anti-Leishmania drugs.
引用
收藏
页码：1541 / 1548
页数：8
相关论文
共 69 条
[1]   The relationship between leishmaniasis and AIDS:: the second 10 years [J].
Alvar, Jorge ;
Aparicio, Pilar ;
Aseffa, Abraham ;
Den Boer, Margriet ;
Canavate, Carmen ;
Dedet, Jean-Pierre ;
Gradoni, Luigi ;
Ter Horst, Rachel ;
Lopez-Velez, Rogelio ;
Moreno, Javier .
CLINICAL MICROBIOLOGY REVIEWS, 2008, 21 (02) :334-+
[2]   In vitro cytocidal effects on Trypanosoma brucei and inhibition of Leishmania major GP63 by peptidomimetic metalloprotease inhibitors [J].
Bangs, JD ;
Ransom, DA ;
Nimick, M ;
Christie, G ;
Hooper, NM .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2001, 114 (01) :111-117
[3]   PERSPECTIVES IN BIOCHEMISTRY AND BIOPHYSICS - FAMILIES AND CLANS OF SERINE PEPTIDASES [J].
BARRETT, AJ ;
RAWLINGS, ND .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 318 (02) :247-250
[4]  
BARRETT AJ, 1994, METHOD ENZYMOL, V244, P1
[5]   Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (04) :684-703
[6]  
Berman J, 2006, INDIAN J MED RES, V123, P289
[7]   Protein turnover and differentiation in Leishmania [J].
Besteiro, Sebastien ;
Williams, Roderick A. M. ;
Coombs, Graham H. ;
Mottram, Jeremy C. .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2007, 37 (10) :1063-1075
[8]   HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review [J].
Bierman, Wouter F. W. ;
van Agtmael, Michiel A. ;
Nijhuis, Monique ;
Danner, Sven A. ;
Boucher, Charles A. B. .
AIDS, 2009, 23 (03) :279-291
[9]   Pentamidine uptake and resistance in pathogenic protozoa: past, present and future [J].
Bray, PG ;
Barrett, MP ;
Ward, SA ;
de Koning, HP .
TRENDS IN PARASITOLOGY, 2003, 19 (05) :232-239
[10]  
Caldas AJM, 2001, T R SOC TROP MED HYG, V95, P1
1234567